We found for
Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

The Lower Drug Costs Now Act and Pharmaceutical Innovation

How is Quality of Life Measured for Health Technology Assessments?

Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study

Policy Options for Formulary Development in Middle-income Countries
